Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + toripalimab with gemcitabine + cisplatin for unresectable cholangiocarcinoma
ChiCTR2400085526Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib, toripalimab, gemcitabine and cisplatin in cholangiocarcinoma (CCA), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Started Jun 2024; status: recruiting.
02
Drugs
surufatinibtoripalimabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2400085526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085526.